AID Inhibitors

Activation-induced cytidine deaminase (AID) stands as a central player in the intricate molecular processes underlying the adaptive immune response, particularly in the context of immunoglobulin (Ig) diversification. AID is primarily expressed in activated B cells and functions as a DNA-editing enzyme, catalyzing the deamination of cytosine to uracil in the variable regions of Ig genes. This deliberate introduction of mutations is a pivotal step in the processes of somatic hypermutation (SHM) and class-switch recombination (CSR), both of which contribute to the generation of diverse antibody repertoires. By introducing point mutations in the variable regions of Ig genes during SHM, AID diversifies the antibody repertoire, enabling the immune system to produce antibodies with varying affinities for antigens. In the context of CSR, AID mediates the exchange of constant regions of Ig genes, altering the effector function of antibodies without changing their antigen specificity. The inhibition of AID represents a nuanced avenue of research aimed at unraveling the intricacies of the immune response. Given the pivotal role of AID in shaping the antibody repertoire, inhibiting AID activity modulate the diversification processes and impact the antibody response. Various mechanisms can be explored for AID inhibition, ranging from the identification of small molecules that directly interact with the enzyme to the exploration of endogenous regulatory pathways that can modulate its activity. Investigating the molecular mechanisms of AID inhibition can shed light on the regulation of antibody diversity and immune responses. Additionally, understanding the consequences of AID inhibition can provide insights into interventions for conditions associated with dysregulated immune responses. This avenue of research contributes to the broader scientific understanding of immune regulation and the molecular mechanisms governing antibody diversification.